In the latest trading session, Lannett closed at $12.26, marking a +1.16% move from the previous day. This change outpaced the S&P 500's 0.19% gain on the day. Elsewhere, the Dow lost 0.11%, while the tech-heavy Nasdaq added 0.81%.
Prior to today's trading, shares of the generic drug company had gained 5.67% over the past month. This has outpaced the Medical sector's loss of 1.57% and the S&P 500's gain of 0.56% in that time.
Investors will be hoping for strength from LCI as it approaches its next earnings release. The company is expected to report EPS of $0.20, down 54.55% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $121.42 million, down 21.69% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.25 per share and revenue of $537.86 million. These totals would mark changes of -46.81% and -17.94%, respectively, from last year.
Any recent changes to analyst estimates for LCI should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.53% higher within the past month. LCI is holding a Zacks Rank of #1 (Strong Buy) right now.
In terms of valuation, LCI is currently trading at a Forward P/E ratio of 9.67. This valuation marks a discount compared to its industry's average Forward P/E of 16.98.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 53, which puts it in the top 21% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Image: Bigstock
Lannett (LCI) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Lannett closed at $12.26, marking a +1.16% move from the previous day. This change outpaced the S&P 500's 0.19% gain on the day. Elsewhere, the Dow lost 0.11%, while the tech-heavy Nasdaq added 0.81%.
Prior to today's trading, shares of the generic drug company had gained 5.67% over the past month. This has outpaced the Medical sector's loss of 1.57% and the S&P 500's gain of 0.56% in that time.
Investors will be hoping for strength from LCI as it approaches its next earnings release. The company is expected to report EPS of $0.20, down 54.55% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $121.42 million, down 21.69% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.25 per share and revenue of $537.86 million. These totals would mark changes of -46.81% and -17.94%, respectively, from last year.
Any recent changes to analyst estimates for LCI should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.53% higher within the past month. LCI is holding a Zacks Rank of #1 (Strong Buy) right now.
In terms of valuation, LCI is currently trading at a Forward P/E ratio of 9.67. This valuation marks a discount compared to its industry's average Forward P/E of 16.98.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 53, which puts it in the top 21% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.